VNRX Share Price Performance
US$0.33
-0.29 (-46.38%)
84.9% undervalued intrinsic discount
US$2.20
Fair Value
Price US$0.33
AnalystConsensusTarget US$2.20
AnalystHighTarget US$3.00
AnalystLowTarget US$1.00
Fair ValueUS$2.20
Share Pricen/a
VolitionRx Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
VNRX Community Narratives
AN
Fair Value US$2.2 84.9% undervalued intrinsic discount
Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$3 88.9% undervalued intrinsic discount
Epigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$1 66.7% undervalued intrinsic discount
Early Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential
Catalysts About VolitionRx VolitionRx develops blood based diagnostic tests built on its Nu.Q nucleosome platform for applications across human and veterinary health. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$2.2
84.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
311.46% p.a.
Profit Margin
77.04%
Future PE
5.34x
Price in 2029
US$2.03
Epigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care
Catalysts About VolitionRx VolitionRx develops and commercializes Nu.Q nucleosome-based blood tests for cancer, NETosis-related diseases and veterinary diagnostics. What are the underlying business or industry changes driving this perspective?Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
88.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
429.78% p.a.
Profit Margin
87.64%
Future PE
3x
Price in 2028
US$2.28
Early Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains
Catalysts About VolitionRx VolitionRx develops and commercializes blood based Nu.Q assays that use nucleosome and chromatin biology to detect and monitor cancer and NETosis related diseases in humans and animals. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1
66.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
79.77% p.a.
Profit Margin
0.13%
Future PE
167.44x
Price in 2028
US$0.01
Trending Discussion
Recently Updated Narratives
AN
Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential
Fair Value: US$2.2 84.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Epigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care
Fair Value: US$3 88.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Early Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains
Fair Value: US$1 66.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
VolitionRx Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.19
- 100.00%
- -1,554.31%
- -28.6%
About VNRX
- Founded
- n/a
- Employees
- 75
- CEO
- WebsiteView website
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
